The current stock price of YDES is 11.82 USD. In the past month the price decreased by -4.68%.
ChartMill assigns a technical rating of 3 / 10 to YDES.
ChartMill assigns a fundamental rating of 3 / 10 to YDES. While YDES seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months YDES reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -10100% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.17% | ||
| ROE | -27.74% | ||
| Debt/Equity | 0 |
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B |
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
YD BIO LTD
12F, No. 3, Xingnan Street, Nangang District
Taipei City TAIPEI TW
Employees: 5
Phone: 88623820330
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
The current stock price of YDES is 11.82 USD.
YDES does not pay a dividend.
YDES has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
YD BIO LTD (YDES) currently has 5 employees.
YD BIO LTD (YDES) has a market capitalization of 833.55M USD. This makes YDES a Small Cap stock.